EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome

Valeria Santini iD, Angela Consagra iD

British Journal of Haematology · 2025-07 · 207 (1) · 15-26

DOI: 10.1111/bjh.20126 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 02.05.2025. Verfasst von Valeria Santini und 1 weiteren Autor:innen. Beteiligte Einrichtung: MDS Unit, DMSC-Hematology, University of Florence, AOU Careggi, Florence, Italy. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Hematinics, Recombinant Fusion Proteins, Activin Receptors, Type II. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence from a unique randomized Phase 3 trial and accumulated evidence in many trials, providing support to an already widely utilized therapeutic option. Luspatercept, a more recently approved agent, is a ligand trap for transforming growth factor beta (TGF‐β) pathway, whose activation is associated with impaired terminal erythroid maturation in MDS. Luspatercept facilitates late‐stage erythroid differentiation, improving transfusion‐dependent anaemia in LR‐MDS, and has shown activity after ESA failure in MDS‐ring sideroblasts (RS) and in all subtypes of MDS ESA naïve transfusion‐dependent patients. Due to the recent approval of luspatercept also in ESA naïve LR‐MDS, it has become crucial to determine the optimal treatment algorithm for anaemic LR‐MDS, before and after transfusion dependence. ESAs and luspatercept are characterized by distinct mechanisms of action, and their integration into treatment strategies is already possible, but requires further evidence to maximize efficacy and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesHematinicsRecombinant Fusion ProteinsActivin Receptors, Type IIImmunoglobulin Fc FragmentsAnemiaHumans

Stichwörter der Autor:innen

ESAsanaemiaerythropoietinlow‐risk myelodysplastic syndromesluspatercepttransfusion dependence

Substanzen

luspaterceptHematinicsRecombinant Fusion ProteinsActivin Receptors, Type IIImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • MDS Unit, DMSC-Hematology, University of Florence, AOU Careggi, Florence, Italy.

ORCID-Profile: Valeria Santini, Angela Consagra

Förderung

  • Fondazione AIRC per la ricerca sul cancro ETS

Zitieren

APA

Santini, V., & Consagra, A. (2025). How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome. British Journal of Haematology, 207(1), 15-26. https://doi.org/10.1111/bjh.20126

Vancouver

Santini V, Consagra A. How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome. British Journal of Haematology. 2025;207(1):15-26. doi:10.1111/bjh.20126

BibTeX
@article{Santini2025,
  author = {Santini, Valeria and Consagra, Angela},
  title = {How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {1},
  pages = {15--26},
  doi = {10.1111/bjh.20126}
}
Kostenlos starten →